Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Groop, L. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Groop, L. C.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 15, Issue 6 737-754, Copyright © 1992 by American Diabetes Association

ARTICLES

Sulfonylureas in NIDDM

LC Groop
Fourth Department of Medicine, Helsinki University Hospital, Finland.

Sulfonylureas have represented the backbone of oral therapy in non-insulin-dependent diabetes mellitus for greater than 30 yr. Despite this, our knowledge about the mode of actions of these agents is limited, and the use of them is far from rational. Sulfonylureas lower blood glucose concentrations primarily by stimulating insulin secretion. The evidence for clinically significant extrapancreatic effects is scanty. Therefore, the effect of sulfonylurea is limited to patients with preserved beta-cell function, with the best effect observed in the early stages of the disease. Sulfonylurea treatment is often started relatively late and is continued when the agents can no longer achieve the treatment goals. Drug dosages are increased to maximum recommended doses, although there is no evidence for a dose-response relationship between the sulfonylurea dose and its biological effect. To rationalize the use of sulfonylureas, we should ask the questions to whom, how much, and for how long? The decision to stop treatment is as important as the decision to start treatment.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Diabetes CareHome page
D. M. Nathan, J. B. Buse, M. B. Davidson, E. Ferrannini, R. R. Holman, R. Sherwin, and B. Zinman
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
Diabetes Care, January 1, 2009; 32(1): 193 - 203.
[Abstract] [Full Text] [PDF]

Home page
 Evid Based Complement Alternat MedHome page
S. L. Badole, N. M. Patel, P. A. Thakurdesai, and S. L. Bodhankar
Interaction of Aqueous Extract of Pleurotus pulmonarius (Fr.) Quel-Champ. with Glyburide in Alloxan Induced Diabetic Mice
Evid. Based Complement. Altern. Med., June 1, 2008; 5(2): 159 - 164.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes Spectr.Home page
P. Hollander
Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People With Diabetes
Diabetes Spectr, July 1, 2007; 20(3): 159 - 165.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
D. Q. Pham, H. Cohen, and V. Chu
Inhaled Human [rDNA Origin] Insulin, a Novel Formulation for Diabetes Mellitus
J. Clin. Pharmacol., July 1, 2007; 47(7): 890 - 903.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
R J Heine, M Diamant, J-C Mbanya, and D M Nathan
Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure?
BMJ, December 9, 2006; 333(7580): 1200 - 1204.
[Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
T. L. Skaer, D. A. Sclar, and L. M. Robison
Trends in the Prescribing of Oral Agents for the Management of Type 2 Diabetes Mellitus in the United States, 1990-2001: Does Type of Insurance Influence Access to Innovation?
The Diabetes Educator, November 1, 2006; 32(6): 940 - 953.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. M. Nathan, J. B. Buse, M. B. Davidson, R. J. Heine, R. R. Holman, R. Sherwin, and B. Zinman
Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
Diabetes Care, August 1, 2006; 29(8): 1963 - 1972.
[Full Text] [PDF]

Home page
 CMAJHome page
S. H. Simpson, S. R. Majumdar, R. T. Tsuyuki, D. T. Eurich, and J. A. Johnson
Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study
Can. Med. Assoc. J., January 17, 2006; 174(2): 169 - 174.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
T. S. Hannon, G. Rao, and S. A. Arslanian
Childhood Obesity and Type 2 Diabetes Mellitus
Pediatrics, August 1, 2005; 116(2): 473 - 480.
[Abstract] [Full Text] [PDF]

Home page
 Clin. DiabetesHome page
I. B. Hirsch, R. M. Bergenstal, C. G. Parkin, E. Wright Jr., and J. B. Buse
A Real-World Approach to Insulin Therapy in Primary Care Practice
Clin. Diabetes, April 1, 2005; 23(2): 78 - 86.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
J. B. Buse, R. R. Henry, J. Han, D. D. Kim, M. S. Fineman, A. D. Baron, and for the Exenatide-113 Clinical Study Group
Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes
Diabetes Care, November 1, 2004; 27(11): 2628 - 2635.
[Abstract] [Full Text] [PDF]

Home page
 Hum Exp ToxicolHome page
S Bolkent, R Yanardag, O Karabulut-Bulan, and O Ozsoy-Sacan
The morphological and biochemical effects of glibornuride on rat liver in experimental diabetes
Human and Experimental Toxicology, May 1, 2004; 23(5): 257 - 264.
[Abstract] [PDF]

Home page
 Diabetes CareHome page
B. Ludvik, B. Neuffer, and G. Pacini
Efficacy of Ipomoea batatas (Caiapo) on Diabetes Control in Type 2 Diabetic Subjects Treated With Diet
Diabetes Care, February 1, 2004; 27(2): 436 - 440.
[Abstract] [Full Text] [PDF]

Home page
 J BiochemHome page
K.-H. Park and T. Akaike
Visualization of the Specific Interaction of Sulfonylurea-Incorporated Polymer with Insulinoma Cell Line MIN6
J. Biochem., February 1, 2004; 135(2): 179 - 183.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. Ostergard, K. B. Degn, M.-A. Gall, R. D. Carr, J. D. Veldhuis, M. K. Thomsen, R. A. Rizza, and O. Schmitz
The Insulin Secretagogues Glibenclamide and Repaglinide Do Not Influence Growth Hormone Secretion in Humans but Stimulate Glucagon Secretion during Profound Insulin Deficiency
J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 297 - 302.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
J J Meier, B Gallwitz, W E Schmidt, A Mugge, and M A Nauck
Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?
Heart, January 1, 2004; 90(1): 9 - 12.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
U. A Shukla, E. M Chi, and K.-H. Lehr
Glimepiride Pharmacokinetics in Obese Versus Non-Obese Diabetic Patients
Ann. Pharmacother., January 1, 2004; 38(1): 30 - 35.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
M. T. Sheehan
Current Therapeutic Options in Type 2 Diabetes Mellitus: A Practical Approach
Clin. Med. Res., July 1, 2003; 1(3): 189 - 200.
[Abstract] [Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
A. D. Morris
Addressing Dosing Frequency in Diabetes: A Simple Approach to Improving Adherence to Therapy and Clinical Outcomes
The Diabetes Educator, May 1, 2003; 29(3): 440 - 453.
[PDF]

Home page
 DiabetesHome page
S. Efendic, A. M. Efanov, P.-O. Berggren, and S. V. Zaitsev
Two Generations of Insulinotropic Imidazoline Compounds
Diabetes, December 1, 2002; 51(90003): S448 - 454.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. St. John Sutton, M. Rendell, P. Dandona, J. F. Dole, K. Murphy, R. Patwardhan, J. Patel, and M. Freed
A Comparison of the Effects of Rosiglitazone and Glyburide on Cardiovascular Function and Glycemic Control in Patients With Type 2 Diabetes
Diabetes Care, November 1, 2002; 25(11): 2058 - 2064.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. M. Nathan
Initial Management of Glycemia in Type 2 Diabetes Mellitus
N. Engl. J. Med., October 24, 2002; 347(17): 1342 - 1349.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. M. Efanov, I. B. Appelskog, S. M. Abdel-Halim, A. Khan, R. Branstrom, O. Larsson, C.-G. Ostenson, H.-J. Mest, P.-O. Berggren, S. Efendic, et al.
Insulinotropic activity of the imidazoline derivative RX871024 in the diabetic GK rat
Am J Physiol Endocrinol Metab, January 1, 2002; 282(1): E117 - E124.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
N. Itabashi, K. Okada, S. Muto, N. Fujita, T. Ohta, J.-i. Miyazaki, Y. Asano, and T. Saito
A Novel Enhancer of Insulinotrophic Action by High Glucose (JTT-608) Stimulates Insulin Secretion from Pancreatic beta -Cells via a New Cellular Mechanism
J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 953 - 960.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
M. Morishita, Y. Iwasaki, E. Yamamori, A. Nomura, N. Mutsuga, M. Yoshida, M. Asai, Y. Oiso, and H. Saito
Antidiabetic Sulfonylurea Enhances Secretagogue-Induced Adrenocorticotropin Secretion and Proopiomelanocortin Gene Expression in Vitro
Endocrinology, September 1, 2000; 141(9): 3313 - 3318.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
S. Campbell
Management of Type 2 Diabetes in the Geriatric Patient
Journal of Pharmacy Practice, August 1, 2000; 13(4): 263 - 276.
[Abstract] [PDF]

Home page
 CirculationHome page
S. M. Haffner, L. Mykkanen, A. Festa, J. P. Burke, and M. P. Stern
Insulin-Resistant Prediabetic Subjects Have More Atherogenic Risk Factors Than Insulin-Sensitive Prediabetic Subjects : Implications for Preventing Coronary Heart Disease During the Prediabetic State
Circulation, March 7, 2000; 101(9): 975 - 980.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
S. J. Jacober and J. R. Sowers
An Update on Perioperative Management of Diabetes
Arch Intern Med, November 8, 1999; 159(20): 2405 - 2411.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
R. A. DeFronzo
Pharmacologic Therapy for Type 2 Diabetes Mellitus
Ann Intern Med, August 17, 1999; 131(4): 281 - 303.
[Abstract] [Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
D. A. Sclar, L. M. Robison, T. L. Skaer, W. M. Dickson, C. M. Kozma, and C. E. Reeder
Sulfonylurea Pharmacotherapy Regimen Adherence in a Medicaid Population: Influence of Age, Gender, and Race
The Diabetes Educator, July 1, 1999; 25(4): 531 - 538.
[PDF]

Home page
 J Am Coll CardiolHome page
K. N. Garratt, P. A. Brady, N. L. Hassinger, D. E. Grill, A. Terzic, and D. R. Holmes Jr.
Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction
J. Am. Coll. Cardiol., January 1, 1999; 33(1): 119 - 124.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
M. R. Burge, K. Schmitz-Fiorentino, C. Fischette, C. R. Qualls, and D. S. Schade
A Prospective Trial of Risk Factors for Sulfonylurea-Induced Hypoglycemia in Type 2 Diabetes Mellitus
JAMA, January 14, 1998; 279(2): 137 - 143.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
E. Mukai, H. Ishida, S. Kato, Y. Tsuura, S. Fujimoto, A. Ishida-Takahashi, M. Horie, K. Tsuda, and Y. Seino
Metabolic inhibition impairs ATP-sensitive K+ channel block by sulfonylurea in pancreatic beta -cells
Am J Physiol Endocrinol Metab, January 1, 1998; 274(1): E38 - E44.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
M. Higuchi, K. Miyagi, S. Kayo, and M. Sakanashi
Acceleration of stiffness in underperfused diabetic rat hearts by glyburide, a KATP channel blocker, and its prevention by levcromakalim and insulin
Cardiovasc Res, August 1, 1997; 35(2): 303 - 314.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. J. Bailey and R. C. Turner
Metformin
N. Engl. J. Med., February 29, 1996; 334(9): 574 - 579.
[Full Text] [PDF]

Home page
 NEJMHome page
R. A. DeFronzo, A. M. Goodman, and The Multicenter Metformin Study Group
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
N. Engl. J. Med., August 31, 1995; 333(9): 541 - 549.
[Abstract] [Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
J. J. Tanja
Jon J. Tanja, RPh, Ms, Fascp; Theresa M. Langlass, RPh, PharmD
The Diabetes Educator, January 1, 1995; 21(6): 509 - 514.
[PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1992 by the American Diabetes Association.